Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to examine effects of movement training with the aid of rhythmic auditory stimulation (RAS) on reducing severity of dyskinesia and bradykinesia in at-risk individuals and schizophrenia patients. The investigators hypothesize that training with the aid of RAS reduced severity of bradykinesia and dyskinesia in at-risk individuals as well as in schizophrenia patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| schizophrenia- RAS | Experimental | Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS). |
|
| schizophrenia- no RAS | Active Comparator | Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS. |
|
| at risk- RAS | Experimental | At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS. |
|
| at risk- no RAS | Active Comparator | At-risk individuals in the control group will receive upper-limb training without the aid of RAS. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rhythmic auditory stimulation (RAS) for schizophrenia patients | Behavioral | A mobile application, "metronome beats" developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday. |
| Measure | Description | Time Frame |
|---|---|---|
| Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) | normalized movement time (representing severity of parkinsonism). Unit: second/mm | Within one week right before the 1st session of the intervention |
| Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) | normalized movement time (representing severity of parkinsonism). Unit: second/mm | Within one week right after the last session of the intervention |
| Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) | normalized number of movement units (representing severity of dyskinesia). Unit: units/mm | Within one week right before the 1st session of the intervention |
| Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK) | normalized number of movement units (representing severity of dyskinesia). Unit: units/mm | Within one week right after the last session of the intervention |
Not provided
Not provided
For at-risk individuals:
The inclusion criteria for at-risk individuals are:
The inclusion criteria for healthy controls are:
At-risk participants and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.
For schizophrenia patients:
The inclusion criteria for schizophrenia patients are:
The inclusion criteria for healthy controls are:
Patients and healthy controls will be excluded if they have any neurological / musculoskeletal dysfunction that may affect their upper-limb movements.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shu-Mei Wang, PhD | Contact | 852-27664197 | shumei.wang@polyu.edu.hk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hong Kong Polytechnic University | Recruiting | Kowloon | Hong Kong |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| No RAS for schizophrenia patients | Behavioral | The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task. |
|
| RAS for at-risk individuals | Behavioral | A mobile application, "metronome beats" developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day. |
|
| No RAS for at-risk individuals | Behavioral | The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task. |
|
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D011618 | Psychotic Disorders |
| D020734 | Parkinsonian Disorders |
| D020820 | Dyskinesias |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided